Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Net Margin (2016 - 2025)

Adma Biologics' Net Margin history spans 13 years, with the latest figure at 35.48% for Q4 2025.

  • For Q4 2025, Net Margin fell 5971.0% year-over-year to 35.48%; the TTM value through Dec 2025 reached 28.8%, down 1755.0%, while the annual FY2025 figure was 28.8%, 1755.0% down from the prior year.
  • Net Margin reached 35.48% in Q4 2025 per ADMA's latest filing, up from 27.14% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 95.19% in Q4 2024 to a low of 114.26% in Q1 2021.
  • Average Net Margin over 5 years is 9.56%, with a median of 4.13% recorded in 2023.
  • Peak YoY movement for Net Margin: soared 11552bps in 2021, then crashed -5971bps in 2025.
  • A 5-year view of Net Margin shows it stood at 30.01% in 2021, then grew by 21bps to 23.59% in 2022, then surged by 161bps to 14.33% in 2023, then soared by 564bps to 95.19% in 2024, then crashed by -63bps to 35.48% in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Net Margin are 35.48% (Q4 2025), 27.14% (Q3 2025), and 28.05% (Q2 2025).